Introduction:Basic information about CAS 4097-22-7|2',3'-Dideoxyadenosine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
2',3'-Dideoxyadenosine is an inhibitor of HIV replication[1]. Antiretroviral activity[1]. Antiviral efficacy[1].
Related Catalog
Signaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection
Target
HIV[1]
In Vitro
2',3'-Dideoxyadenosine inhibits HIV-1 and simian immunodeficiency virus (SIV) in MT-4 cells with EC50s of 5.27 and 5.3 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in human T-lymphocyte CEM cells with EC50s of 4 μM and 8 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in Molt 4/C8 cells with EC50s of 4 μM and 5.5 μM, respectively. 2',3'-Dideoxyadenosine inhibits HIV-1 and HIV-2 in C8166 cells with EC50s of 17 μM and 22 μM, respectively. 2',3'-Dideoxyadenosine inhibits murine sarcoma virus (MSV) in C3H/3T3 cells with an EC50 of 24 μM[1].
References
[1]. Balzarini J, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 1997 Jun 30;410(2-3):324-8.
Chemical & Physical Properties
Density
1.8±0.1 g/cm3
Boiling Point
539.1±60.0 °C at 760 mmHg
Melting Point
181-184 °C(lit.)
Molecular Formula
C10H13N5O2
Molecular Weight
235.242
Flash Point
279.9±32.9 °C
Exact Mass
235.106918
PSA
99.08000
LogP
-0.43
Vapour Pressure
0.0±1.5 mmHg at 25°C
Index of Refraction
1.822
InChIKey
WVXRAFOPTSTNLL-NKWVEPMBSA-N
SMILES
Nc1ncnc2c1ncn2C1CCC(CO)O1
Storage condition
2-8°C
Toxicological Information
CHEMICAL IDENTIFICATION
RTECS NUMBER :
AU7358900
CHEMICAL NAME :
Adenosine, 2',3'-dideoxy-
CAS REGISTRY NUMBER :
4097-22-7
BEILSTEIN REFERENCE NO. :
0619924
LAST UPDATED :
199612
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C10-H13-N5-O2
MOLECULAR WEIGHT :
235.28
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1320 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19600 mg/kg/28D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
MUTATION DATA
TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
9 gm/kg/3D (Continuous)
REFERENCE :
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991
Iron chelation is a promising therapeutic strategy for cancer that works, in part, by inducing overexpression of N-myc downstream-regulated gene 1 protein (NDRG1), a known growth inhibitor and metasta...
The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.
Cancer Res. 75(1) , 16-21, (2015)
Identifying modifiers of glioma risk in patients with type I neurofibromatosis (NF1) could help support personalized tumor surveillance, advance understanding of gliomagenesis, and potentially identif...
Metformin as adjunct antituberculosis therapy.
Sci. Transl. Med. 6(263) , 263ra159, (2014)
The global burden of tuberculosis (TB) morbidity and mortality remains immense. A potential new approach to TB therapy is to augment protective host immune responses. We report that the antidiabetic d...